Advanced search
Publication Cover
Emerging Microbes & Infections Volume 11, 2022 - Issue 1
Submit an article Journal homepage
3,982
Views
9
CrossRef citations to date
0
Altmetric
Coronaviruses

mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern

Haomeng Wanga CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Zhao Chenb State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaView further author information
,
Zhenghua Wanga CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Jin Lia CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Zhihong Yana CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Jinbo Yuana CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Airu Zhub State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaView further author information
,
Lan Chenb State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaView further author information
,
Ye Liua CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Chenlong Hua CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Ali Zhua CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Guowei Lia CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Yuehu Lia CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaView further author information
,
Jie Dengc CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Liqiao Mac CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Xiuwen Suic CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Wei Miaoc CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Junqiang Lic CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Xiuyu Zhengc CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Jinhua Piaoc CanSino Biologics, Tianjin, People’s Republic of ChinaView further author information
,
Yanfeng Yaoh Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaView further author information
,
Juhong Raoi State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaView further author information
,
Chao Shani State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of China;j Hubei Jiangxia Laboratory, Wuhan, People’s Republic of ChinaView further author information
,
Zhiming Yuanh Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-3234-9616View further author information
ORCID Icon,
Jincun Zhaob State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China;e Institute of Infectious Disease, Guangzhou Eighth People’s Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China;f Guangzhou Laboratory, Bio-Island, Guangzhou, People’s Republic of China;g Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Tao Zhua CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People’s Republic of China;c CanSino Biologics, Tianjin, People’s Republic of China;d CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1550-1553 | Received 01 Mar 2022, Accepted 19 May 2022, Published online: 04 Jun 2022
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by a grant from National Key R&D Program of China [No. 2021YFC2301700].
Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.